Frontiers in Neuroscience,
Journal Year:
2020,
Volume and Issue:
14
Published: Oct. 6, 2020
The
locus
coeruleus
(LC)
has
long
been
underappreciated
for
its
role
in
the
pathophysiology
of
Alzheimer's
disease
(AD),
Parkinson's
(PD),
and
other
neurodegenerative
disorders.
While
AD
PD
are
distinct
clinical
presentation,
both
characterized
by
prodromal
protein
aggregation
LC,
late-stage
degeneration
comorbid
conditions
indicative
LC
dysfunction.
Many
these
early
studies
were
limited
to
post-mortem
histological
techniques
due
LC's
small
size
location
deep
brainstem.
Thus,
there
is
a
growing
interest
utilizing
vivo
imaging
as
predictor
preclinical
processes
biomarker
progression.
Simultaneously,
neuroimaging
animal
models
holds
promise
identifying
alterations
circuits,
but
thus
far
underutilized.
still
infancy,
handful
have
reported
effects
single
gene
mutations
pathology
on
function
using
various
techniques.
Furthermore,
combining
optogenetics
or
chemogenetics
allows
interrogation
network
connectivity
response
changes
activity.
purpose
this
article
twofold:
(1)
review
what
magnetic
resonance
(MRI)
positron
emission
tomography
(PET)
revealed
about
dysfunction
potential
humans,
(2)
explore
how
can
be
used
test
hypotheses
derived
from
data
establish
mechanistic
framework
inform
LC-focused
therapeutic
interventions
alleviate
symptoms
impede
Acta Neuropathologica,
Journal Year:
2021,
Volume and Issue:
141(5), P. 631 - 650
Published: Jan. 11, 2021
Abstract
Alzheimer’s
disease
(AD)
is
neuropathologically
characterized
by
the
intracellular
accumulation
of
hyperphosphorylated
tau
and
extracellular
deposition
amyloid-β
plaques,
which
affect
certain
brain
regions
in
a
progressive
manner.
The
locus
coeruleus
(LC),
small
nucleus
pons
brainstem,
widely
recognized
as
one
earliest
sites
neurofibrillary
tangle
formation
AD.
Patients
with
AD
exhibit
significant
neuronal
loss
LC,
resulting
marked
reduction
its
size
function.
vastly
innervates
several
brain,
primary
source
neurotransmitter
norepinephrine
(NE)
central
nervous
system.
Considering
that
NE
major
modulator
behavior,
contributing
to
neuroprotection
suppression
neuroinflammation,
degeneration
LC
ultimate
dysregulation
LC–NE
system
has
detrimental
effects
brain.
In
this
review,
we
detail
neuroanatomy
function
essential
role
neuroprotection,
how
dysregulated
We
discuss
AD-related
neuropathologic
changes
mechanisms
neurons
are
selectively
vulnerable
insult.
Further,
elucidate
neurotoxic
de-innervation
both
locally
at
projection
sites,
augments
pathology,
progression
severity.
summarize
preservation
could
be
used
treatment
other
neurodegenerative
diseases
affected
degeneration.
Nature Aging,
Journal Year:
2024,
Volume and Issue:
4(5), P. 625 - 637
Published: April 25, 2024
Abstract
Autopsy
studies
indicated
that
the
locus
coeruleus
(LC)
accumulates
hyperphosphorylated
tau
before
allocortical
regions
in
Alzheimer’s
disease.
By
combining
vivo
longitudinal
magnetic
resonance
imaging
measures
of
LC
integrity,
positron
emission
tomography
and
cognition
with
autopsy
data
transcriptomic
information,
we
examined
whether
changes
precede
deposition
specific
genetic
features
underlie
LC’s
selective
vulnerability
to
tau.
We
found
integrity
preceded
medial
temporal
lobe
accumulation,
together
these
processes
were
associated
lower
cognitive
performance.
Common
gene
expression
profiles
between
LC–medial
lobe–limbic
map
biological
functions
protein
transport
regulation.
These
findings
advance
our
understanding
spatiotemporal
patterns
initial
spreading
from
disease
pathology.
can
be
a
promising
indicator
for
identifying
time
window
when
individuals
are
at
risk
progression
underscore
importance
interventions
mitigating
spread.
Antioxidants,
Journal Year:
2021,
Volume and Issue:
10(1), P. 61 - 61
Published: Jan. 6, 2021
Iron
accumulation
and
neuroinflammation
are
pathological
conditions
found
in
several
neurodegenerative
diseases,
including
Alzheimer’s
disease
(AD)
Parkinson’s
(PD).
inflammation
intertwined
a
bidirectional
relationship,
where
iron
modifies
the
inflammatory
phenotype
of
microglia
infiltrating
macrophages,
turn,
these
cells
secrete
diffusible
mediators
that
reshape
neuronal
homeostasis
regulate
entry
into
brain.
Secreted
include
cytokines
reactive
oxygen/nitrogen
species
(ROS/RNS),
notably
hepcidin
nitric
oxide
(·NO).
Hepcidin
is
small
cationic
peptide
with
central
role
regulating
systemic
homeostasis.
Also
present
cerebrospinal
fluid
(CSF),
can
reduce
export
from
neurons
decreases
through
blood–brain
barrier
(BBB)
by
binding
to
exporter
ferroportin
1
(Fpn1).
Likewise,
·NO
selectively
converts
cytosolic
aconitase
(c-aconitase)
regulatory
protein
(IRP1),
which
regulates
cellular
its
response
elements
(IRE)
located
mRNAs
iron-related
proteins.
Nitric
oxide-activated
IRP1
impair
during
neuroinflammation,
triggering
accumulation,
especially
mitochondria,
leading
death.
In
this
review,
we
will
summarize
findings
connect
support
their
causal
association
processes
observed
AD
PD.
Frontiers in Systems Neuroscience,
Journal Year:
2021,
Volume and Issue:
15
Published: Sept. 24, 2021
Pathological
proteins
contributing
to
Alzheimer’s
disease
(AD)
are
known
disrupt
normal
neuronal
functions
in
the
brain,
leading
unbalanced
excitatory-inhibitory
tone,
distorted
synchrony,
and
network
oscillations.
However,
it
has
been
proposed
that
abnormalities
activity
directly
contribute
pathogenesis
of
disease,
fact
demonstrated
induction
synchronized
40
Hz
gamma
oscillation
networks
by
sensory
stimulation
reverses
AD-related
pathological
markers
transgenic
mice
carrying
human
genes.
Based
on
these
findings,
current
study
evaluated
whether
non-invasive
inducing
cortical
is
clinically
beneficial
for
AD
patients.
Patients
with
mild
moderate
(
n
=
22)
were
randomized
active
treatment
group
14;
therapy)
or
sham
8).
Participants
received
precisely
timed,
visual
auditory
stimulations
during
eye-closed
condition
induce
steady-state
oscillations
1-h
daily
sessions
over
a
6-month
period.
exposed
similar
designed
not
evoke
observed
During
trial,
nighttime
activities
patients
monitored
continuous
actigraphy
recordings,
their
functional
abilities
measured
Disease
Cooperative
Study
–
Activities
Daily
Living
(ADCS-ADL)
scale.
Results
this
therapy
was
well
tolerated
throughout
period
all
subjects.
receiving
showed
significantly
reduced
periods,
contrast,
deterioration
sleep
quality
also
expected,
significant
decline
ADCS-ADL
scores,
whereas
fully
maintained
These
findings
confirm
safe
application
demonstrate
high
adherence
treatment.
Furthermore,
first
time
clinical
effects
reported,
justifying
expanded
longer
trials
explore
additional
benefits
disease-modifying
properties
therapy.
Clinical
Trial
Registration:
clinicaltrials.gov
,
identifier:
NCT03556280.
Brain,
Journal Year:
2021,
Volume and Issue:
145(6), P. 1924 - 1938
Published: Dec. 14, 2021
Abstract
The
locus
coeruleus
is
the
initial
site
of
Alzheimer’s
disease
neuropathology,
with
hyperphosphorylated
Tau
appearing
in
early
adulthood
followed
by
neurodegeneration
dementia.
Locus
dysfunction
contributes
to
pathobiology
experimental
models,
which
can
be
rescued
increasing
norepinephrine
transmission.
To
test
augmentation
as
a
potential
disease-modifying
therapy,
we
performed
biomarker-driven
phase
II
trial
atomoxetine,
clinically-approved
transporter
inhibitor,
subjects
mild
cognitive
impairment
due
disease.
design
was
single-centre,
12-month
double-blind
crossover
trial.
Thirty-nine
participants
and
biomarker
evidence
were
randomized
atomoxetine
or
placebo
treatment.
Assessments
collected
at
baseline,
6-
(crossover)
12-months
(completer).
Target
engagement
assessed
CSF
plasma
measures
metabolites.
Prespecified
primary
outcomes
levels
IL1α
TECK.
Secondary/exploratory
included
clinical
measures,
analyses
amyloid-β42,
Tau,
pTau181,
mass
spectrometry
proteomics
immune-based
targeted
inflammation-related
cytokines,
well
brain
imaging
MRI
fluorodeoxyglucose-PET.
Baseline
demographic
similar
across
arms.
Dropout
rates
5.1%
for
2.7%
placebo,
no
significant
differences
adverse
events.
Atomoxetine
robustly
increased
levels.
IL-1α
TECK
not
measurable
most
samples.
There
treatment
effects
on
cognition
outcomes,
expected
given
short
duration.
associated
reduction
pTau181
compared
but
change
amyloid-β42.
also
significantly
altered
abundances
protein
panels
linked
pathophysiologies,
including
synaptic,
metabolism
glial
immunity,
CDCP1,
CD244,
TWEAK
osteoprotegerin
proteins.
Treatment
brain-derived
neurotrophic
factor
reduced
triglycerides
plasma.
Resting
state
functional
showed
inter-network
connectivity
between
insula
hippocampus.
Fluorodeoxyglucose-PET
atomoxetine-associated
uptake
hippocampus,
parahippocampal
gyrus,
middle
temporal
pole,
inferior
gyrus
fusiform
carry-over
6
months
after
In
summary,
safe,
tolerated
achieved
target
prodromal
pTau,
normalized
synaptic
function,
activity
key
lobe
circuits.
Further
study
warranted
repurposing
drug
slow
progression.
Alzheimer s & Dementia,
Journal Year:
2023,
Volume and Issue:
19(5), P. 2182 - 2196
Published: Jan. 15, 2023
Abstract
The
neuromodulatory
subcortical
system
(NSS)
nuclei
are
critical
hubs
for
survival,
hedonic
tone,
and
homeostasis.
Tau‐associated
NSS
degeneration
occurs
early
in
Alzheimer's
disease
(AD)
pathogenesis,
long
before
the
emergence
of
pathognomonic
memory
dysfunction
cortical
lesions.
Accumulating
evidence
supports
role
behavioral
neuropsychiatric
manifestations
featured
AD.
Experimental
studies
even
suggest
that
AD‐associated
drives
brain
neuroinflammatory
status
contributes
to
progression,
including
exacerbation
Given
important
pathophysiologic
etiologic
roles
involve
AD
stages,
there
is
an
urgent
need
expand
our
understanding
mechanisms
underlying
vulnerability
more
precisely
detail
clinical
progression
changes
Here,
Professional
Interest
Area
International
Society
Advance
Research
Treatment
highlights
knowledge
gaps
about
within
provides
recommendations
priorities
specific
research,
biomarker
development,
modeling,
intervention.
Highlights
Neuromodulatory
degenerate
pathological
stages.
pathophysiology
exacerbated
by
degeneration.
symptoms
dementia.
Biomarkers
integrity
would
be
value‐creating
dementia
care.
present
strategic
prospects
disease‐modifying
therapies.
Journal of Neuroscience Research,
Journal Year:
2020,
Volume and Issue:
98(12), P. 2406 - 2434
Published: Sept. 1, 2020
Abstract
Locus
coeruleus
(LC)
is
the
main
noradrenergic
(NA)
nucleus
of
central
nervous
system.
LC
degenerates
early
during
Alzheimer's
disease
(AD)
and
NA
loss
might
concur
to
AD
pathogenesis.
Aside
from
neurons,
terminals
provide
dense
innervation
brain
intraparenchymal
arterioles/capillaries,
modulates
astrocyte
functions.
The
term
neurovascular
unit
(NVU)
defines
strict
anatomical/functional
interaction
occurring
between
glial
cells,
vessels.
NVU
plays
a
fundamental
role
in
coupling
energy
demand
activated
regions
with
regional
cerebral
blood
flow,
it
includes
blood–brain
barrier
(BBB),
an
active
neuroinflammation,
participates
also
glymphatic
alteration
involved
pathophysiology
through
several
mechanisms,
mainly
related
relative
oligoemia
impairment
structural
functional
BBB
integrity,
which
contributes
intracerebral
accumulation
insoluble
amyloid.
We
review
existing
data
on
morphological
features
LC‐NA
NVU,
as
well
its
contribution
proper
functioning.
After
introducing
experimental
linking
AD,
have
repeatedly
shown
key
neuroinflammation
increased
amyloid
plaque
formation,
we
discuss
potential
mechanisms
by
modulation
contribute
Surprisingly,
thus
far
not
so
many
studies
tested
directly
these
models
has
been
lesioned
experimentally.
Clarifying
pathogenesis
may
disclose
therapeutic
targets
for
AD.